This week marks the sixth anniversary of the date that Bob Kyle, Henry Duong, and I incorporated Advera Health Analytics. We started this journey with a mission to improve patient outcomes by making drug safety data more accessible and actionable. We spent the early years developing our technologies, building our data delivery platform, and subjecting our early methodologies to peer review. Two years ago we began to commercialize our enterprise data product and since then we’ve grown exponentially.
To date our focus has been to use real world data to fill the information gap that exists about drug safety. Over the years we’ve developed extensive algorithms that clean and optimize real world data, score drugs based on their relative safety and cost to the healthcare system, and accurately alert for serious, unknown side effects. We have debunked and overcome previously accepted limitations about the value of drug safety data, and our software platform now delivers this actionable information to some of the most prestigious healthcare organizations in the country.
After six years we have fulfilled our initial mission, built an amazing team, and created a need-to-have product. As our product has evolved based on feedback from our clients, so too has our vision and mission. Post-marketing FAERS data provides a critical piece of the puzzle, but it is just one piece. In order to complete the picture, we need to look back for evidence that has been reported in clinical trials and published in literature, and also further into the real world from other data sources such as payer claims and health system EHR.
Marrying those three elements will create a powerful and evolving database of actionable information for the healthcare industry. We will be able to track, compare, and analyze the safety and efficacy of a drug through its lifecycle.
This is our new quest and like all big missions the process starts with a few small steps. For the past few months our team has been diligently working to incorporate annotated safety and efficacy data from clinical trial results into our platform. We’ve mined and optimized data from thousands of trials in ClinicalTrials.gov and hundreds of published trials in academic journals. If you want to get an idea of how these data will coalesce, check out our latest Drug Safety Monitor report on the new Hep C drug Zepatier. Very soon we’ll launch this new module for key indications as a beta offering to our clients.
If we’ve learned anything over the past six years, it’s that a drug’s safety and efficacy record is always changing. We’ve loudly criticized the healthcare system for relying solely on early data from clinical trials while ignoring the shifting safety profile in the real world. By incorporating clinical evidence into our platform, we’re going to make it easier for our clients to see, track, and understand the evolution as a drug makes its way out of the clinical environment and into real world use.
Nothing like this has ever been done before, and for good reason - it’s extremely hard to curate the data and even harder to present them effectively. But it was also extremely hard to take the broken down drug safety data from FDA and making it into a reliable and valuable source of predictive and actionable intelligence. This is what we do best and we’re excited for the next phase in our company’s development.
Having these safety and efficacy data and comparisons available on demand and in an easy-to-use format will enable our clients to make better decisions. In doing so, we will greatly improve patient outcomes.
Which is exactly what we set out to accomplish six years ago this week.
To see a table comparing the clinical evidence of Zepatier vs. Harvoni and Sovaldi, see our latest Drug Safety Monitor report.
To learn more about Advera Health’s quest for better evidence, please contact us.